2025
Estimated Effectiveness of Nirsevimab Against Respiratory Syncytial Virus
Xu H, Aparicio C, Wats A, Araujo B, Pitzer V, Warren J, Shapiro E, Niccolai L, Weinberger D, Oliveira C. Estimated Effectiveness of Nirsevimab Against Respiratory Syncytial Virus. JAMA Network Open 2025, 8: e250380. PMID: 40063022, PMCID: PMC11894488, DOI: 10.1001/jamanetworkopen.2025.0380.Peer-Reviewed Original ResearchConceptsRSV-positive casesCase-control studyRSV infectionLRTI-associated hospitalizationsWeeks postimmunizationLong-acting monoclonal antibodiesTest-negative case-control studyClinical settingRespiratory syncytial virusMultivariate logistic regressionYale New Haven Health SystemRSV diseaseEmergency department dataState immunization registryRSV seasonSyncytial virusNirsevimabPolymerase chain reactionClinical trialsLRTIInfantsPotential confoundersMonoclonal antibodiesBroader outcomesDisease severity
2023
Failure to Complete Multidose Vaccine Series in Early Childhood.
Michels S, Niccolai L, Hadler J, Freeman R, Albers A, Glanz J, Daley M, Newcomer S. Failure to Complete Multidose Vaccine Series in Early Childhood. 2023, 152 PMID: 37489285, PMCID: PMC10389773, DOI: 10.1542/peds.2022-059844.Peer-Reviewed Original ResearchConceptsVaccine seriesVaccination patternsUS childrenAdditional vaccine doseEarly childhood immunizationVaccine dosePreventable diseaseChildhood immunizationSeries completionNumber of childrenSociodemographic factorsInsurance coverageStrong associationOptimal protectionEarly childhoodBinomial regressionChildrenDosesAssociationStructural barriersCoverage goalsVaccinationImmunization
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply